Podcasts about Emory School

HMI 30th anniversary podcast series To Teach is to Learn Twice: A conversation with Holly Gooding   This episode of the Harvard Macy Institute podcast features Holly Gooding, a well know faculty leader within HMI. Holly is an internal medicine and adolescent medicine physician by training, with an impressive clinical research portfolio in cardiovascular risk assessment for teens and young adults. Trained in California and then Boston, she now serves as the Medical Director of Adolescent Medicine at Children's Healthcare of Atlanta. Holly is a star medical educator and scholar. In addition to co-directing the Harvard Macy Program for Educators in the Health Professions, she is associate dean for Professional Development and Education at Emory School of Medicine, where she fosters professional development for medical trainees and faculty. In this inspirational conversation, Holly gives us insights into her parallel and overlapping careers as clinician, researcher, educator and scholar. She highlights the influence of mentors and peers on her career decisions and educational practice. She sees opportunities in being given big jobs to do, e.g. developing the ‘science of learning' theme in the Educators program. We ponder about the role of AI in clinical and educational practice, and feel grateful to be part of a community of practice that will be helping to understand and guide our work. Holly is endlessly generous with her praise of others who contribute to and nurture the Harvard Macy Institute, and we are grateful for her ongoing contribution. Your host for this episode is Victoria Brazil (Educators, '05, Leaders '07, Assessment ‘10). Victoria is Professor of Emergency Medicine at Bond University Faculty of Health Sciences and Medicine. She hosts the HMI podcast and is co-producer ofSimulcast-a podcast about healthcare simulation.

Gut issues, bloating, fatigue, and stubborn weight? You're NOT alone! In this episode, I sit down with Dr. Will Bulsiewicz (Dr. B), an award-winning gastroenterologist and New York Times bestselling author, to chat about why gut health is the foundation of everything—and how YOU can start healing today. Known on instagram as The Gut Health MD, Dr. B shares his personal gut health transformation and why his 16 years of medical training didn't teach him about the power of food, so he took it into his own hands. We uncover science-backed strategies to heal your gut naturally and he should absolutely open your mind to things you wouldn't have heard of before that impact your gut health!! We Cover: The biggest gut health mistakes you might be making How your gut controls your immune system, metabolism, mood, and more The surprising connection between sleep and gut health The power of morning sunlight in regulating digestion and metabolism Natural ways to support GLP-1 (your body's version of Ozempic!) How stress, loneliness, and mental health (including unhealed  trauma) affect gut health The best natural strategies for constipation relief Food intolerances & sensitivities—why some people react to gluten, dairy, and FODMAPs And so much more… If you're struggling with bloating, fatigue, gut issues, or stubborn weight, this episode is for you!   More about Dr B: Residing in Charleston, South Carolina with his family, Dr. Will Bulsiewicz, also known as "Dr B," is an award-winning gastroenterologist and a leading authority on gut health. He is the New York Times bestselling author of "Fiber Fueled" and "The Fiber Fueled Cookbook," and the founder of the gut health supplement company, 38TERA.  As the U.S. Medical Director for the personalised nutrition company ZOE and an Adjunct Assistant Professor of Medicine at Emory School of Medicine, Dr. B is dedicated to making gut health education accessible. His prolific contributions to the field include over twenty peer-reviewed articles and more than forty national presentations.  LINKS: Learn more from Dr B: 38TERA supplement: Click HERE to shop (Code BEC for 10% off)  Instagram: @38tera  Instagram: @theguthealthmd TikTok: @theguthealthmd_ Website: theplantfedgut.com/   Learn more from me: Download my FREE eBook with 4 15 minute meals: click HERE Start your weight loss, gut healing and anti-inflammatory journey now with my 3 Week Body  Reset  Continue your journey and figuring out YOUR own balance in the Health with Bec Tribe  Follow me on instagram: @health_with_bec Visit my website: Click HERE  

Rob Friedman aka the "Pitching Ninja" joins Diggin' At Home! Rob talks about the drastic evolution in MLB content over the last decade and how analytics are used in today's game. Rob explains how we went from almost getting banned from twitter for posting copyrighted MLB content to now hosting a show with the league. He has been as influential as anyone in the baseball content space in not only bringing a fresh perspective to pitching, but pushing the boundaries of what's possible for baseball content consumption. Rob has a found a way to reach both the casual fan and MLB pitchers, many of which have come to him for advice over the years. His content has had such influence that one time Yu Darvish interrupted a dinner Rob was at with his wife to ask about a pitching grip! Rob breaks down all of the pitching trends that are out there with Peter Moylan & Eric Hosmer.Rob takes us back to his early days, graduating from UNC and then the Emory School of Law where he graduated top of his class. For Rob, baseball was always his hobby and not something he thought could become a full-time opportunity. In fact, he was in tax and corporate law for years before he started his own company 'Digital Envoy' which sold to Landmark Communications in 2007. -----------------GuestRob Friedman /⁠⁠@pitchingninja⁠⁠⁠HostsEric Hosmer /⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ @hosmer305⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Peter Moylan / ⁠⁠@petermoylan⁠Interact with the Diggin' Deep Crew on:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ / ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Facebook⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ / ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Twitter⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ / ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TikTok⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Advertising & Partnership inquiries: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠diggindeep@moonballmedia.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠a⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ MoonBall Media⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Podcast

March 11, 2025, will mark 5 years since the World Health Organization (WHO) declared COVID-19 a pandemic. Between January 22, 2020, and March 10, 2023, Johns Hopkins University recorded over 676 million confirmed COVID-19 cases worldwide and more than 6.8 million related deaths. In the US alone, it reported over 103 million cases and more than 1 million deaths during this timeframe. Although the WHO declared an end to the public health emergency on May 5, 2023, followed by the CDC on May 11, COVID-19 continues to impact thousands of individuals worldwide. On this episode of Managed Care Cast, we're speaking with Jenny Han, MD, a COVID-19 expert from Emory School of Medicine and Grady Hospital in Atlanta, Georgia. We'll explore the current state of COVID-19, including risk factors, treatments, and the impacts of long COVID. We will also discuss prevention strategies, vaccination efforts, and future steps to improve COVID-19 care and outcomes.

For Wilbur Lam, innovation in medicine is all about improving patient care. As associate dean of innovation at Emory School of Medicine, Lam sees great promise in microtechnology to understand, diagnose, and treat disease. At his research lab and at the bedside, he's combining bioengineering and medicine with the goal of making disease detection and treatment easier, faster, and more effective. Hosted on Acast. See acast.com/privacy for more information.

Dr. Will Bulsiewicz, affectionately known as "Dr. B," is a distinguished gastroenterologist, globally renowned gut health authority, and a bestselling author of "Fiber Fueled" and "The Fiber Fueled Cookbook" recognized by the New York Times, Wall Street Journal, and USA Today. He is an Adjunct Assistant Professor of Medicine at Emory School of Medicine and the visionary Founder of 38TERA, a leading gut health supplement company.Dr. B is dedicated to democratizing health knowledge as the U.S. Medical Director of ZOE. His scholarly work includes over twenty articles in top-tier scientific journals like Nature Medicine, and he has delivered more than forty presentations at national forums, including sessions with Congress and the USDA. He has educated over 10,000 students on enhancing gut health.His academic credentials include a Bachelor's degree from Vanderbilt University, a medical degree from Georgetown University, and a Master's in Clinical Investigation from Northwestern University. Dr. B was the chief medical resident at Northwestern and the chief gastroenterology fellow at The University of North Carolina, and received the highest award given by both his residency and fellowship. He completed an epidemiology fellowship on a grant from the National Institutes of Health at UNC's prestigious Gillings School of Global Public Health.Dr. B resides in Charleston, South Carolina with his family. Connect with him on Instagram and Facebook at @theguthealthmd, on TikTok at @theguthealthmd_, or visit his website at theplantfedgut.com to join his free email list explore more about his work and insights on gut health.www.theplantfedgut.comhttps://www.facebook.com/theguthealthmd/https://www.instagram.com/theguthealthmd/https://www.tiktok.com/@theguthealthmdThank you so much for listening! I use fitness and movement to help women prevent and overcome pelvic floor challenges like incontinence and organ prolapse. There is help for women in all life stages! Every Woman Needs A Vagina Coach! Please make sure to LEAVE A REVIEW and SUBSCRIBE to the show for the best fitness and wellness advice south of your belly button. *******************I recommend checking out my comprehensive pelvic health education and fitness programs on my Buff Muff AppYou can also join my next 28 Day Buff Muff Challenge https://www.vaginacoach.com/buffmuffIf you are feeling social you can connect with me… On Facebook https://www.facebook.com/VagCoachOn Instagram https://www.instagram.com/vaginacoach/On Twitter https://twitter.com/VaginaCoachOn The Web www.vaginacoach.comGet your Feel Amazing Vaginal Moisturizer Here

The race to develop an effective COVID-19 vaccine showed the world just how powerful the immune system can be to prevent serious illness. Rafi Ahmed discusses how understanding the immune system is key to developing lifesaving vaccines. Ahmed, the Charles Howard Candler Professor of Microbiology and Immunology at Emory School of Medicine, directs the Emory Vaccine Center and is co-leader of the Cancer Immunology Research Program at Emory's Winship Cancer Institute. Hosted on Acast. See acast.com/privacy for more information.

Jenn is an Emory University School of Law Graduate and currently works as the Owner CEO and Certified Life Coach at Jenn Deal Coaching and as Of Counsel at Thomas Horstemeyer. In this episode, I sit down with Jenn Deal, a trademark lawyer and career coach whose journey is a masterclass in self-discovery, resilience, and the power of a growth mindset.We start with Jenn's time at Emory School of Law, where her love for learning made law school both a challenging and deeply fulfilling experience. Jenn shares how a serendipitous encounter with a professor ignited her passion for trademark law, setting her on the path to where she is today.As we delve deeper, Jenn opens up about the struggles she faced—battles with mindset, self-talk, and the pursuit of perfection. She offers insights into how she navigated these challenges, from her clerkship to her current roles. Her reflections on what she wishes she had known earlier in her career are invaluable for anyone on a similar path.The conversation takes a fascinating turn as we explore one of my favorite topics: the growth mindset. Jenn dives into self-talk, self-awareness, and the power of incremental changes. She also introduces the concept of toxic positivity, a new idea for me, but one that's crucial in the world of personal development.Jenn's wealth of knowledge in growth mindset and self-help makes this episode a treasure trove of wisdom. Trust me, you don't want to miss it!Jenn's LinkedIn: linkedin.com/in/jenn-deal-coachingBe sure to check out the Official Sponsors for the Lawyers in the Making Podcast:Rhetoric - takes user briefs and motions and compares them against the text of opinions written by judges to identify ways to tailor their arguments to better persuade the judges handling their cases. Rhetoric's focus is on persuasion and helps users find new ways to improve their odds of success through more persuasive arguments. Find them here: userhetoric.comThe Law School Operating System Recorded Course - Use this Link (https://www.lisablasser.com/offers/nAytQusX?coupon_code=LSOSNATE10) or go to LisaBlasser.com for 10% off her recorded course! This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit lawyersinthemaking.substack.com

Authors:  Sebouh Bazikian - PGY1 at Emory School of Medicine Integrated Vascular Surgery Program   Miguel F. Manzure - vascular surgery attending the University of Southern California Keck School of Medicine involved in complex limb preservation Core Resources: Rutherford Chapters: 107, 108, 109 (Includes further information on anatomy), 112 Additional Resources: Relevant trials BEST CLI: https://pubmed.ncbi.nlm.nih.gov/36342173/ BASIL 2: https://pubmed.ncbi.nlm.nih.gov/37116524/ Relevant Audible Bleeding episodes Audible Bleeding Endovascular Basics: https://open.spotify.com/episode/7jDpkhGMauBslk8SBklCyB?si=75f0931773d24b91 Audible Bleeding eBook, CLTI Chapter: https://adam-mdmph.quarto.pub/vascular-surgery-exam-prep/clti.html Anything else useful WIFI: https://pubmed.ncbi.nlm.nih.gov/24126108/ GLASS: https://pubmed.ncbi.nlm.nih.gov/31159978/ Monophasic, Biphasic, Triphasic Waveforms: https://pubmed.ncbi.nlm.nih.gov/32667274/ Underlying disease featured in episode - peripheral arterial disease Pathophysiology/etiology narrowing of peripheral arteries caused by atherosclerotic plaques causing arterial insufficiency distal to the point of occlusion. This reduces oxygen supply to the muscles. When oxygen demand increases but cannot be met, it leads to an imbalance such as pain and poor wound healing.  Risks: smoking, diabetes, hypertension, dyslipidemia, and older age Equal prevalence in men and women, peak incidence age 60-80 Coexists with CAD, DM, stroke, Afib, and renal disease Patient Presentation 20-50% asymptomatic, rest can be intermittent claudication, rest pain, or tissue loss claudication=pain or discomfort felt in the legs due to a lack of blood flow, especially during physical activity.  CLTI=chronic limb threatening ischemia: rest pain lasting greater than 2 weeks or nonhealing ulcers and gangrene Physical exam:  decreased skin temperature, less hair on the legs, brittle nails, atrophied muscles, shiny skin, livedo reticularis. Absent or diminished pulses Buerger sign Diagnosis Ankle brachial index:

It's In the News! A look at the top diabetes stories and headlines happening now. Top stories this week: The Eversense CGM could soon be approved for one year of continuous use, the first generic GLP-1 medication is launched, a new company tauts and all-in-one sensor and pump infusion set, a new diabetes accessory in the Roblox game, and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom  Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens  Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX In the news is brought to you by Edgepark simplify your diabetes journey with Edgepark XX The first ever generic GLP-1 medication will soon be available in the US. It's a generic of Victoza, originally approved by the FDA in 2010 for diabetes, is part of the same class of drugs that includes Ozempic and Mounjaro. Liraglutide is Glucagon-like peptide-1 receptor agonists (otherwise known as GLP-1s or GLP-1 RAs) are a class of incretin drugs that mimic the body's natural hormones to help treat diabetes and obesity. However, the popularity of the drugs has spiraled out of control at times, leading to shortages and supply chain issues in the US and abroad.  The arrival of a GLP-1 generic drug provides reasons to be hopeful for doctors and patients alike, but there are also caveats. Couple of caveats - liraglutide is injected once daily (vs. weekly) and many doctors say it doesn't work as well for as many people as semaglutide and terzepatide. No confirmation on the price Two other generic options are being developed and could launch in December 2024. Patents for newer GLP-1 medications like Ozempic and Wegovy won't expire until several years down the road https://www.healthline.com/health-news/victoza-generic-glp1-drug-available XX Senseonics plans to launch a 365-day sensor in the U.S. in the fourth quarter of this year. A one-year Eversense CGM could be a game changer for the company.   In 2024, Senseonics expects to more than double U.S. new patient starts and increase the global installed base by around 50%. The growth is built on the current 180-day version of Senseonics' implantable Eversense CGM. Eversense's 180-day sensor can need calibrating twice a day, something Senseonics CEO Tim Goodnow said “has been a competitive disadvantage.” Users calibrate the 365-day sensor once a week. Senseonics is in talks with insulin pump manufacturers about integrating its Eversense CGM with their devices but has yet to commit to a timeline for finalizing an agreement. https://www.medtechdive.com/news/senseonics-365-day-cgm-2025-sales/719717/ XX People who take Ozempic or Wegovy may have a higher risk of developing a rare form of blindness, a new study suggests. Still, doctors say it shouldn't deter patients from using the medicines to treat diabetes or obesity.   Last summer, doctors at Mass Eye and Ear noticed an unusually high number of patients with non-arteritic anterior ischemic optic neuropathy, or NAION, a type of eye stroke that causes sudden, painless vision loss in one eye.   The condition is relatively rare — up to 10 out of 100,000 people in the general population may experience it — but the doctors noted three cases in one week, and each of those patients was taking semaglutide medications. The risk was found to be greatest within the first year of receiving a prescription for semaglutide.   The study, published Wednesday in the medical journal JAMA Ophthalmology, cannot prove that semaglutide medications cause NAION. And the small number of patients — an average of about 100 cases were identified each year — from one specialized medical center may not apply to a broader population. The ways that semaglutides interact with the eyes are not entirely understood. And the exact cause of NAION is not known either. The condition causes damage to the optic nerve, but there is often no warning before vision loss.   For now, patients who are taking semaglutide or considering treatment should discuss the risks and benefits with their doctors, especially those who have other known optic nerve problems such as glaucoma or preexisting visual loss, experts say https://www.reuters.com/business/healthcare-pharmaceuticals/wegovy-ozempic-linked-with-sight-threatening-eye-disorder-study-2024-07-03/ XX We got some updates at ADA about the over the counter CGMS Dexcom Stelo and Abbot's Libre. Dexom plans a late august launch of stelo, which you'll order from their website – it won't be physically in stores. Abbott also plans to sell its wellness-oriented Lingo device this summer through an e-commerce website. That's a sensor that's been available in other coutnires for a while, but was recently okayed in the US. It's not meant for people with diabetes. The Libre Rio is designed or adulst with type 2 who don't use insulin. No timing yet on that product's launch. Neither Abbott nor Dexcom have disclosed pricing for the upcoming products. https://www.medtechdive.com/news/abbott-dexcom-over-the-counter-cgm-launch/719928/ XX Insulet is looking to expand the label for its Omnipod 5 insulin pump for people with Type 2 diabetes. The company said Friday it recently filed with the Food and Drug Administration. Insulet presented study results at the American Diabetes Association's 84th Scientific Sessions that evaluated Omnipod 5 in people with Type 2 diabetes who were taking basal insulin or multiple daily injections. The results showed “substantial improvements in blood glucose outcomes and overall quality of life,” said study chair Francisco Pasquel, an associate professor of endocrinology at Emory School of Medicine. Omnipod 5 is currently cleared in the U.S. for people with Type 1 diabetes. Insulet hopes to expand the pump to people with Type 2 diabetes, with an expected launch in early 2025. The FDA has not yet cleared any automated insulin delivery systems for people with Type 2 diabetes, Insulet said. The company has a basal-only insulin pump, called Omnipod Go, that was cleared for people with Type 2 diabetes last year, but it does not connect to other devices. Even though Omnipod 5 is not currently indicated for Type 2 diabetes, doctors prescribe it for their patients with full reimbursement since the pharmacy channel doesn't distinguish between Type 1 or Type 2 patients, J.P. Morgan analyst Robbie Marcus wrote in a research note on Sunday. https://www.medtechdive.com/news/insulet-omnipod-5-type-2-diabetes-study/719644/ XX In the keynote address at the American Diabetes Association annual conference, FDA Commissioner Dr. Robert Califf expressed concerns about the rising rates of diabetes in the U.S. Though revolutionary medications and technologies for diabetes and weight loss continue to emerge, these treatments are vastly underused. The silver lining lies with type 1 diabetes therapies, which are showing great promise in clinical trials. “For the larger epidemic of type 2 diabetes, we're failing right now,” Califf said. “I don't say that lightly.” A huge problem, Califf said, is access. While most health insurance plans cover medical devices and medications for diabetes, without insurance, costs add up quickly. Ozempic, for example, costs nearly $1,000 per month without insurance. Studies have found that regardless of insurance status, roughly 26% of Americans skipped or delayed treatment due to cost. https://diatribe.org/diabetes-management/fda-commissioner-says-were-failing-people-type-2-diabetes XX Embecta presented two abstracts at the American Diabetes Association Scientific Sessions last weekend making the case for its insulin patch pump for Type 2 diabetes. The company submitted the device for Food and Drug Administration clearance in late 2023. The diabetes device company developed a patch pump with a larger insulin reservoir that can hold up to 300 units. Embecta, which is better known for making equipment such as pen needles and insulin syringes, has been developing its first patch pump. The company found that a device with a larger insulin reservoir could provide longer wear times and fewer disposable patches. https://www.medtechdive.com/news/embecta-insulin-patch-pump-volume-american-diabetes-association/719779/ XX   Pump/CGM sensor in one The niaa signature patch pump, shown with a watch displaying current blood sugar level The niaa signature patch pump has a manual bolus button and is part of an in-development AID system. Swiss technology maker Pharmasens demonstrated a new semi-reusable tubeless patch pump and glucose sensor in the same compact device, called the niia signature, which the company says can be worn for five days.   The top of the device, which includes Bluetooth connectivity and the electronic and mechanical parts to control the pump, separates from the disposable 300-unit reservoir along with the adhesive used to attach the device to the body via a steel cannula. A small button on the device allows manual bolusing. The company says an AID system will manage the device, controlled by smartphone.   PharmaSens' simpler basal-bolus patch pump, the niia essential, was submitted for FDA approval in late December. Availability of the niia signature AID system has yet to be announced. https://diatribe.org/diabetes-technology/diabetes-technology-display-ada-2024 XX Edgepark Commercial XX New international consensus statement offers guidance on the care and monitoring of people who are at high risk for type 1 diabetes (T1D). This is all about screening and testing for islet autoantibodies. These individuals are classified as: At risk or Stage 0 (single autoantibody or transient single autoantibody), Stage 1 (two or more autoantibodies with normoglycemia), and Stage 2 (two or more autoantibodies with dysglycemia but without symptoms and not yet meeting diagnostic criteria for Stage 3 clinical T1D). The document was presented on June 24, 2024 in a 90-minute symposium at the American Diabetes Association's annual Scientific Sessions and published simultaneously in both Diabetes Care and Diabetologia. "This is not guidance around who to screen or when to screen. This is guidance for the hundreds of thousands of people around the world who have participated in screening, mostly through research programs, and have been identified with positive autoantibodies and need care in the clinical setting," panel co-chair Anastasia Albanese-O'Neill, PhD, APRN, CDCES, of Breakthrough T1D, told Medscape Medical News.   The recommendations also include when to start insulin, and how to provide education and psychosocial support to individuals and family members of those given the early-stage T1D diagnosis. https://www.medscape.com/viewarticle/experts-advise-early-risk-monitoring-type-1-diabetes-2024a1000bpo XX Roblox has added a diabetic option, complete with insuli pen and Dexcom You can find it in the marketplace JDRF – now breakthrough t1d – started a world in roblox a couple of years ago as well Roblox is a super popular online game that a lot of kids play. https://www.roblox.com/games/5823990610/Breakthrough-T1D-World XX FFL next week! Join us again soon!

Dr. Beth-Sarah Wright, an Atlanta-based author, dynamic speaker, and strategic thought partner, writes to inspire transformation and change in communities, institutions, and personal lives. Her impactful work tackles deep-rooted challenges that demand identity shifts and enhanced capacities to achieve lasting, meaningful change. Dr. Wright champions authenticity, striving to align our aspirational identities with our lived realities. Dr. Wright is the author of seven influential books, served for 10 years on the senior leadership team as the director of enrollment management at the largest parish Episcopal school in the country, and serves as an Adjunct Assistant Professor in Psychiatry at Emory School of Medicine.  Key Takeaways: Define yourself: “If I didn't define myself for myself, I would be crunched into other people's fantasies for me and eaten alive” – Audre Lorde Respect the dignity of every human being  Take the time to pause and look again  Your identity is not an obstacle – if it feels like one, it has not been truly seen Be careful of the ideas about certain identities you may project onto others Ask questions – be curious We have the power to write new beginnings and endings to our stories Lead with DIGNITY: Diversity, Identity, Growth, Nurture, Integrity, Transparency, Yield Authenticity is when aspirational identity aligns with lived reality Guest's Media Recommendations: Tiny Love Stories: True Tales of Love in 100 Words or Less (book) edited by Daniel T. Jones and Miya Lee __ Find Guest's work: Dr. Beth-Sarah Wright's Website: https://bethsarahwright.com/ __ For more of Michael's work, visit our website www.incognitotheplay.com or follow us on Instagram @incognitotheplay __ Thanks to Ned Doheny for providing our podcast music! You can find him and his music on Spotify. Editing and co-production of this podcast by Nina Kissinger. Email info@incognitotheplay.com with questions or comments about the show!

While resident education represents the top priority of most otolaryngology departments, few attending surgeons receive formal training on teaching. In this episode of the BackTable ENT podcast, host Dr. Gopi Shah covers surgical education with Dr. Oswaldo Henriquez, rhinologist at Wellstar Health and adjunct associate professor at Emory School of Medicine. --- CHECK OUT OUR SPONSOR Medtronic ENT https://www.medtronic.com/us-en/healthcare-professionals/medical-specialties/ear-nose-throat.html?cmpid=Vanity_URL_MIX_medtronicent-com_202212_US_EN_NS_ENT_FY23 --- SYNPOSIS First, Dr. Henriquez shares his passion for teaching and learning. In his view, surgeons are career-long learners: even established otolaryngologists benefit from surgical coaching. Then, he describes the unique needs of adult learners. When teaching technical skills, Dr. Henriquez emphasizes providing realistic goals, actionable feedback, and opportunities for supervised practice. When teaching “soft skills,” Dr. Henriquez focuses on modeling the professionalism and compassion he expects of his trainees. Finally, the episode concludes with Dr. Henriquez's thoughts on teaching as a skill all academic surgeons should hone. --- TIMESTAMPS 00:00 - Introduction 03:29 - Dr. Enriquez's Journey as a Surgical Educator 07:26 - Teaching Adult Learners 24:14 - Challenges in Modern Surgical Education 31:39 - Setting Goals & Expectations 36:40 - The Importance of Feedback in Surgical Education 43:25 - Modeling & Teaching Surgical “Soft Skills” 53:01 - Learning How to Teach: Lessons From a Surgical Educator --- RESOURCES Dr. Oswaldo Henriquez's Wellstar Profile: https://www.wellstar.org/physicians/oswaldo-henriquez-md Medtronic ENT https://www.medtronic.com/us-en/healthcare-professionals/products/ear-nose-throat.html

About Peter:Dr. Sprague holds the positions of Assistant Professor of Rehabilitation Medicine and Assistant Professor of Orthopaedics in Emory University's School of Medicine. His primary teaching appointment is within the Physical Therapy Division in the Emory School of Medicine where he is the co-course coordinator for the Musculoskeletal Rehabilitation course, the course coordinator for the Introduction to Interventions course, and course coordinator for a course he developed entitled “A Movement System Approach to the Orthopaedic Client.”  He is a Board Certified Clinical Specialist in Orthopaedic Physical Therapy and currently serves on the Committee of Content Experts for the American Board of Physical Therapy Specialties.  Dr. Sprague has extensive clinical experience working with high school and collegiate athletes in an interprofessional team setting and has assisted in the development and implementation of screening procedures assessing for musculoskeletal injury risk for collegiate and professional sports organizations. He has an active research agenda exploring movement as it relates to outcomes following ACL reconstruction and is interested in exploring teaching methodology that promotes learning related to the identification and treatment of movement dysfunction that results in pain and injury or is caused by pain and injury. Dr. Sprague lives in the Atlanta area and enjoys outdoor activities with his wife and 3 dogs.

About Peter:Dr. Sprague holds the positions of Assistant Professor of Rehabilitation Medicine and Assistant Professor of Orthopaedics in Emory University's School of Medicine. His primary teaching appointment is within the Physical Therapy Division in the Emory School of Medicine where he is the co-course coordinator for the Musculoskeletal Rehabilitation course, the course coordinator for the Introduction to Interventions course, and course coordinator for a course he developed entitled “A Movement System Approach to the Orthopaedic Client.”  He is a Board Certified Clinical Specialist in Orthopaedic Physical Therapy and currently serves on the Committee of Content Experts for the American Board of Physical Therapy Specialties.  Dr. Sprague has extensive clinical experience working with high school and collegiate athletes in an interprofessional team setting and has assisted in the development and implementation of screening procedures assessing for musculoskeletal injury risk for collegiate and professional sports organizations. He has an active research agenda exploring movement as it relates to outcomes following ACL reconstruction and is interested in exploring teaching methodology that promotes learning related to the identification and treatment of movement dysfunction that results in pain and injury or is caused by pain and injury. Dr. Sprague lives in the Atlanta area and enjoys outdoor activities with his wife and 3 dogs.

In the episode, we dive deep into the complexities of raising teens in today's world. Join Sarah as she sits down with Atlanta-based criminal defense attorney, Ash Joshi, who brings his unique perspective as both a parent and a successful practitioner. A graduate of Michigan and Emory School of Law, Ash sheds light on the real challenges facing our community and offers valuable insights for parents. Tune in closely, parents, as we explore the issues you need to be aware of. Enjoy!

Georgia's allergy season officially stretches from early spring to late fall. However, according to Atlanta Allergy & Asthma's Pollen counter, pollen has started to spike as early as February this year. Emory School of Medicine Assistant Professor Pedro Lamothe discusses the severity of pollen season, the health risks and what Georgians can do to guard themselves for the rest of the season. Plus, we air WABE education reporter Juma Sei's feature from the “Young Business” series. The story spotlights how a young entrepreneur's passion for music led him to create a pop-up record shop. Lastly, on the morning of what will be the very last Face/Off at the current MJQ Concourse location, Rose talks with DJs Rasta Root and Jah Prince.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Dr. Michelle Wallace is a pediatric cardiologist with Children's Healthcare of Atlanta Cardiology, assistant professor of pediatrics at Emory School of Medicine, and adjunct assistant professor of pediatrics at Morehouse School of Medicine. Join us in a conversation about the importance of pediatric cardiovascular care for children and adolescents. In this conversation Dr. Wallace discusses the connection between heart diseases that begin in childhood and often present in adulthood. She gives practical advice on how families, churches and community organizations can prevent heart diseases in children and adolescents through diet, exercise, family fitness, education and advocacy. Listen and share this conversation widely, because healthy hearts include our children. #hearthealth4children

"When we create these wonderful communities, whether in church, in organizations, in institutions, and in schools, all of that is built around human dignity. If we put dignity at the core, we will be surprised how we can maximize the authenticity of our communities and the authenticity of our togetherness and allow for us really to be intentional about seeing each other's dignity." -Dr. Beth-Sarah WrightIn this episode, Bishop Wright is joined by special guest Dr. Beth-Sarah Wright, author and speaker. Beth-Sarah shares her powerful story of battling clinical depression, and how embracing our vulnerabilities can spark deep healing and foster genuine community. They have a conversation about dignity through the lens of the Baptismal Covenant, the acronym behind her book DIGNITY and the strategies used to create authentic community. Listen in for the full conversation. - - - -Atlanta-based author and speaker, Dr. Beth-Sarah Wright writes to make a difference. She writes to develop the courage for transformation and change, in our communities, our institutions, and our lives. Beth-Sarah is the author of seven books. Her most recent book, The DIGNITY Lens Workbook: Implementing the Seven Strategies for Creating Authentic Community is a companion to her book DIGNITY: Seven Strategies for Creating Authentic Community. DIGNITY is a comprehensive lens through which to view and solve for insidious barriers to authenticity and narrow the gap between who we say we are and who we are in reality. A former college professor at NYU and Spelman College, she currently serves as the Director of Enrollment Management at Holy Innocents' Episcopal School in Atlanta and an Adjunct Assistant Professor in the Department of Psychiatry at Emory School of Medicine. She holds a PhD in Performance Studies from New York University, an MPhil in Anthropology from Cambridge University and a BA (magna cum laude) from Princeton University in Sociology and Afro-American studies.Beth-Sarah is originally from Jamaica and has lived and studied worldwide, from Edinburgh, Scotland to San Juan, Puerto Rico. She is married to Bishop Wright, Bishop of The Episcopal Diocese of Atlanta and they are parents to 5 children.Support the show

Dave and one of his younger sisters were both born with heart defects that required surgery. When Dave was 60, he was diagnosed with an aortic aneurysm. By this time, he had a daughter, Dawn Laney, who was a genetic counselor and professor at the Emory School of Medicine. With Dawn's help, Dave finally arrived at a diagnosis of Cutis Laxa for both himself and his sister. Motivated to help patients receive a diagnosis faster, Dave leveraged his decades long career working with technology in healthcare and Dawn's expertise in genetic counseling to co-found ThinkGenetic, Inc. and the ThinkGenetic Foundation.  Related Resources ThinkGenetic.com ThinkGenetic Foundation --- Send in a voice message: https://podcasters.spotify.com/pod/show/patient-stories-with-grey-genetics/message

Dr. Oluseun Olufade is a board certified orthopedic and sports medicine physician in Atlanta, Georgia. Of his many roles, he works as an Assistant Professor of Orthopedics at Emory School of Medicine and serves various athletic organizations such as, U.S. Soccer, Atlanta Hawks, Emory University and Northview High School. We discussed Atlanta, realities of a sports medicine doctor in America, and avulsion injuries/fractures in adolescent athletes. And we reviewed a unique case study presented at the Isokinetic Football Conference (2022): "How displaced is too displaced? An Avulsion fracture in an adolescent footballer? "Follow for updates: https://www.instagram.com/medicalexpertsinfootballMusic: Adding The Sun by Kevin MacLeodLink: https://incompetech.filmmusic.io/song/5708-adding-the-sun

ASCO: You're listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the voice of the world's oncology professionals. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guests' statements on this podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so data described here may change as research progresses. The theme of the 2023 ASCO Annual Meeting was “Partnering With Patients: The Cornerstone of Cancer Care and Research.” From June 2 to 6 in Chicago, Illinois, and online, cancer researchers and clinicians from around the world gathered to discuss the latest cancer research and how to ensure that all people receive the cancer care they need. In the Research Round Up series, members of the Cancer.Net Editorial Board discuss the most exciting and practice-changing research in their field presented at the meeting and explain what it means for people with cancer. In today's episode, our guests will discuss new research in gynecologic cancers [2:06], multiple myeloma [9:15], and head and neck cancer [16:03]. First, Dr. Lan Coffman discusses new research in ovarian cancer, uterine cancer, and cervical cancer. Dr. Coffman is a physician-scientist and gynecologic oncologist at the Magee-Womens Research Institute and Foundation, and assistant professor in Hematology-Oncology at the University of Pittsburgh School of Medicine. She is also the 2023 Cancer.Net Associate Editor for Gynecologic Cancers. You can view Dr. Coffman's disclosures at Cancer.Net. Dr. Coffman: Hi, my name is Lan Coffman. I'm a physician-scientist at the University of Pittsburgh. I'm a medical oncologist that specializes in gynecologic cancers, and I'm happy to discuss research that was presented on gynecologic cancers at the 2023 ASCO Annual Meeting. I do have a relevant disclosure. I participated in one of the trials I'm going to discuss, a trial called MIRASOL. I was the site principal investigator at University of Pittsburgh. I think there were a lot of interesting studies to highlight, and I wanted to focus on studies involving ovary cancer, endometrial cancer, and cervix cancers as the main sites that we study in the gynecologic oncology world. So when we talk about ovary cancer, I think there was one really impactful study that was presented at ASCO this year, and it was called MIRASOL. And again, this is the study that I also participated in at our hospital at University of Pittsburgh. So it was a large study, so a randomized phase 3 study looking at a drug called mirvetuximab, which is an antibody-drug conjugate. So basically, it's an antibody against a protein that is expressed on ovarian cancer cells and the protein's called folate receptor-alpha. And that antibody basically carries a little poison. And so it's kind of like a Trojan horse. This antibody goes, finds that protein on the tumor cells, and then delivers that poison. And so this drug has been studied and actually was presented last year in a different trial called SORAYA, which showed that it had activity, meaning the drug helped to kill ovarian cancer cells, and actually led to the first approval of this drug in ovary cancer. So this trial was the confirmatory trial, so enrolling more patients to see, actually, is it better than standard-of-care chemotherapy? So this was in women with ovarian cancer that had come back and was platinum resistant, meaning the cancer started to grow within 6 months from the last platinum-based therapy. Women were eligible if they had high expression of this folate receptor-alpha, and they had to have a couple of prior lines of therapy. And then they were randomized, so kind of chosen out of a hat to either be treated with mirvetuximab or with investigator's choice chemotherapy. So one of the chemotherapies we'd use standardly. And so that would be something like taxol, or liposomal doxorubicin, or topotecan. And basically, this study was comparing how well does mirvetuximab work compared to chemotherapy. And importantly, it showed that it improved survival, both progression-free survival, so how long it took before the disease started to grow again, but probably more importantly, actually improved overall survival, so how long a woman lived. And actually changed overall survival from about 16 and a half months compared to 12 months with chemotherapy. And so this was really important and demonstrated that mirvetuximab does actually impact women with ovarian cancer and actually helps women live longer. And that's really hard to do in this setting. And the other nice thing about this trial was that not only did it work well, but there are actually lower side effects with it, and so less women actually had to discontinue their treatment, and they had less what we call adverse events, or basically bad things that had happened from the treatment themselves. So just telling us that this drug is actually well tolerated. Women feel well on it, even when their cancer is shrinking. So I think that was one of the most impactful studies in ovary cancer. Moving on to endometrial cancer. We recently had 2 studies, one called RUBY and one called GY018 that looked at using immunotherapy in combination with chemotherapy in endometrial cancer. And what was presented at ASCO was some follow-up from this RUBY trial, which was basically validating that this combination of adding immunotherapy actually helped. To give you a background, traditionally, women that have endometrial cancer that is advanced staged, meaning spread outside of the uterus itself or has come back, we treat it with chemotherapy. But this study added an immunotherapy called dostarlimab in combination with our standard chemotherapy and actually showed that women were living longer with this, at least in that progression-free survival. We're still waiting on final evaluation. But at ASCO, what they reported was another independent blinded review of the data to show that even when we're really carefully looking at this data, it looks like immunotherapy helps women with endometrial cancer live longer. They also presented quality-of-life data showing that women actually feel better with the addition of the immunotherapy. So I think this is practice changing. And again, this data has been coming out over the last year or so, but I do think this will change the way in which endometrial cancer is treated. And then the final thing I wanted to discuss would be in cervix cancer. And while there wasn't a lot of new data presented here in terms of kind of paradigm shifts or large changes, we did have final survival [data] from the KEYNOTE-826 presented, which is also using immunotherapy along with chemotherapy in cervix cancer. And so this was in women that, again, had advanced-stage cervix cancer. So it was a cervix cancer that had moved beyond the cervix itself or cervix cancer that had come back and was treated with chemotherapy along with another immunotherapy called pembrolizumab. And this was the final survival data that confirmed that the immunotherapy did help women live longer. The survival data was impressive with about a 10-month improvement in overall survival. So how long a woman lived. And so that was really confirmatory of the previous trials. So again, that emphasizes that immunotherapy is moved towards the standard of care in cervix cancer as well. I can't hit all the highlights of the impressive research coming out of ASCO 2023, this is a brief summary of some of the critical studies in gynecologic cancers. ASCO: Thank you, Dr. Coffman. Next, Dr. Sagar Lonial discusses new research in multiple myeloma. Dr. Lonial is a professor of Hematology and Medical Oncology at Winship Cancer Institute at Emory University, where he also serves as Department Chair. He is also the 2023 Cancer.Net Associate Editor for Myeloma. You can view Dr. Lonial's disclosures at Cancer.Net. Dr. Lonial: Hello, I'm Dr. Sagar Lonial from the Emory School of Medicine and the Winship Cancer Institute in Atlanta, Georgia. And today I'm going to discuss some of the really exciting research in the context of multiple myeloma that was presented at the 2023 ASCO Annual Meeting. In terms of my conflicts of interest, I have enrolled patients on many CAR T trials as well as bispecific trials from all of the different companies involved here. So, I do have some engagement with those trials. And one of the studies that I may talk about at the end came from our institution. So I was an investigator on that study as well. When I think about some of the really exciting work that was presented at ASCO this year, there are really 2 big categories of trials that I think were most exciting. And the first is CAR T-cells and moving them earlier and earlier in the disease state. And what we saw at ASCO this year was the CARTITUDE-4 study, which was a randomized phase 3 trial comparing CAR T-cells versus standard treatment in the context of first or second relapsed multiple myeloma. And this was a really important study for us to hear because we know that CAR T-cells are highly effective in the later lines of therapy. A big question at this point is, "Does their efficacy hold up in earlier lines of therapy? And how does it compare in a randomized setting against what we might normally use in that clinical context?" And what I think we were really excited to see at ASCO this year was that CAR T-cells appear to be superior to standard treatment in the context of that randomized phase 3 trial. Now, there were a few patients who were randomized to CAR T-cells who didn't get to the CAR T-cell infusion because their disease progressed in that interval. And that is a challenge that many of us deal with on a regular basis when we think about using a CAR T in a patient. But in general, the treatment was available for almost all patients. And the analysis of benefit as measured by a longer remission duration for the patients who received CAR T cells versus those who didn't was really done on what we call an intent to treat basis. And what that means is if you were randomized to the CAR T arm, even if you didn't get the CAR T, which again was a very small number of patients, you were still evaluated as if you got a CAR. And what I think that tells us is that even taking into account some of those patients who may not get there, there still was significant clinical benefit. And this is really important data for us to have insight into. We've seen this with cilta-cel in CARTITUDE-4. We'd seen similar kinds of findings in KarMMa using ide-cel as the CAR T-cell, although it does appear that the remission duration, at least when you're comparing across trials, appears to be a little bit longer for cilta-cel than what we've seen with ide-cel. But nonetheless, it suggests that even in the context of early relapse, there may be some benefit for CARs over standard therapy. Now, does this mean that CARs are going to replace standard therapy in terms of early relapse? I don't think we know the answer to that right now. I think there's a lot of information that we need to look at to really feel comfortable making that step. The other big set of data I think that we were all very excited about to see at ASCO this year were the T-cell engagers or the bispecifics. And what we saw from a number of different bispecifics was that the efficacy data looks like it continues to hold up. But what to me was really quite exciting was the idea that the T-cell engager could be highly effective even if a patient had seen prior BCMA-directed therapy. And what this means to me is that perhaps if you're progressing on a CAR T-cell, you still may have a pretty reasonable chance at a response, again, to a BCMA-directed therapy with a bispecific. The other way around may not necessarily be the same. And so I think what we learned at this meeting is that the bispecific or T-cell engagers clearly could have activity in the context of prior BCMA-exposed therapy. And I think, as a field, we need to think more about how we define what it means to be resistant to a BCMA-directed therapy. So that I think was really important and exciting and will have relevance in our daily clinical practice. We also saw updates on a different non-BCMA-directed target. So we saw updates on GPRC5D-targeted bispecifics, also known as talquetamab. What I think was really exciting here is we saw a very high overall response rate, modest infectious complications compared to what we've seen with BCMA-directed therapy.   Finally, what I want to wrap up with was a very small study addressing what I think is a pretty significant unmet medical need. And that was a trial from Dr. Nooka at my institution, where we evaluated a combination of carfilzomib with pomalidomide and dexamethasone, or KPD. And we used that specifically as maintenance in the high-risk group. And what we learned from that evaluation is that it appears for patients with high-risk disease that KPD maintenance is better than either carfilzomib and len [lenalidomide] or even bortezomib and lenalidomide, which historically has been what we're using. But there remains an unmet medical need patient population, particularly the double-hit patient population, that even with KPD still didn't have a great outcome overall. So more work for us to do down the road. But certainly, food for thought for many of those other patients that perhaps don't fit into that double-hit classic category. So I think what I've given you is a nice sort of overview of many of the exciting data that were presented at ASCO 2023. Again, go to the website to see additional ones. And thank you again for listening to this brief summary of research in myeloma updates from the 2023 ASCO Annual Meeting. ASCO: Thank you, Dr. Lonial. Finally, Dr. Cristina Rodriguez discusses new research in treating head and neck cancer. Dr. Rodriguez is a medical oncologist at Seattle Cancer Care Alliance, an Associate Professor in the Division of Medical Oncology at the University of Washington, and an Associate Member for solid tumor clinical research at the Fred Hutchinson Cancer Research Center. She is also the 2023 Cancer.Net Associate Editor for Head and Neck Cancers. You can view Dr. Rodriguez's disclosures at Cancer.Net. Dr. Rodriguez: Hello, my name is Cristina Rodriguez, and today I'm going to discuss some new research focusing on head and neck cancer that was presented at our annual ASCO 2023 meeting. As part of my disclosures, my institution receives research funding from CGEN. My takeaway from this meeting was there were a few major themes represented by the research. One of them was research on uncommon cancer types, such as nasopharyngeal cancer and salivary gland cancer. The other major theme and what was exciting for me was research on groups that were typically not represented in clinical trials in head and neck cancer. These include elderly or frail patients with many other comorbid illnesses that might have excluded them from clinical trials. Another theme was research in areas outside the developed world. In other words, resource-restricted countries. There was some exciting research coming out of that. And finally, a few new agents, novel agents that looked to have activity in patients with head and neck cancer that are going to be studied further. So with that, I'm going to start with talking about research that came out of France, presented by Dr. Fayette. This was a clinical trial that focused primarily on the frail elderly population. A group that might make very difficult for one to enter clinical trial because of many different illnesses or not being fit enough. And this group, out of France, looked at a combination of immunotherapy and a gentler lower dose chemotherapy called carboplatin and paclitaxel. Interestingly, in this group, there was very encouraging results, including 71% of patients having an objective response or a reduction in the size of their tumor, and very few patients, less than 5% of patients, having toxicity that required permanent discontinuation of the drug. So I thought this study was particularly interesting and gives us physicians and patients who are in this situation some more options to use when we're in the treatment of head and neck cancer. The next study that I thought was particularly interesting came out of India and was presented by Dr. Kothari. The special thing about this study was that it asked the question of the efficacy of a very low-cost combination for patients with recurrent or metastatic head and neck cancer. It's a combination that we don't tend to use here in the United States, one that involves methotrexate, celecoxib, and erlotinib. This particular clinical trial was carried out in several sites in India, and it randomized patients to this low-cost oral regimen versus physician's choice. In other words, any type of treatment that might involve immunotherapy or antibody therapy. The main issue here being that sometimes many of these therapies are not easily accessible to patients in low-resourced situations. The investigators observed an overall survival advantage, what that means is more patients lived longer when they use the low-cost oral regimen, which was much more practical, much easier for patients to take, and had more success in improving and prolonging the lives of patients. So I thought that that was a particularly important observation. And we forget a lot of times when we're practicing in the United States that a lot of our practice patterns here may not be applicable to low-resource settings. And I think it's very exciting that research is being carried out to answer questions that are relevant to this area. The third abstract that I thought was particularly intriguing was one presented by Dr. Glenn Hanna from Dana-Farber. And it looked at a new drug called BCA101. BCA101 is an antibody that has 2 functions. It inhibits EGFR, or epidermal growth factor receptor, very commonly overexpressed in head and neck squamous cell carcinomas. And it has a dual function, which is it modulates TGFβ, which is an immunosuppressive cytokine within tumor cells. This drug was combined with pembrolizumab in this small study and offered to patients who have never received treatment for recurrent or metastatic head and neck cancer. There was a lot of enthusiasm for this drug because in the 33 patients enrolled in the trial, 48% of them had an objective response, meaning a reduction in the size of their tumor. Anemia was one of the more common side effects that were noted. But the efficacy of this agent in this population, these patients expressed PD-L1 or had a CPS score of 1, was enough to support further study of this drug and a larger clinical trial is going to be carried out looking to see if this drug will have similar efficacy or better efficacy in a larger population. Finally, the last abstract is one that was presented by Dr. Swiecicki. And it was an interesting abstract to me because it examined the activity of another novel agent not FDA-approved for head and neck cancer, called enfortumab vedotin. This is a class of drugs that belong to a group called antibody-drug conjugates. This is an antibody that's directed toward the target called Nectin-4 and has a small chemotherapy payload that's attached to the antibody. Unlike Dr. Hanna's study, this study was a small phase 2 trial that focused on patients who've previously been treated in the recurrent or metastatic setting and are now receiving this drug either as their second or third option after they developed recurrent or metastatic disease. 46 patients were enrolled in this trial, and 24% of patients had an objective response or reduction in the size of this tumor. Although that number doesn't seem very high, it is an encouraging signal because in patients who previously received treatment for head and neck cancer, we tend to see very poor response rates. So this is encouraging given the population that was studied. Another 32% of these patients had what's called stable disease or no significant change in the size of their tumor. So that too is quite encouraging. This drug is going to also move on for further study in head and neck cancer. So I thought that these themes really brought about a lot of excitement for me for the future of treatments in patients with head and neck cancer, not only in developed countries but also in resource-restricted environments. And I look forward to next year and more work being done in these areas. And I'd like to thank you for listening to this brief summary of developments and head and neck cancer presented in the 2023 ASCO Annual Meeting. ASCO: Thank you, Dr. Rodriguez. You can find more research from recent scientific meetings at www.cancer.net. Cancer.Net Podcasts feature trusted, timely, and compassionate information for people with cancer, survivors, and their families and loved ones. Subscribe wherever you listen to podcasts for expert information and tips on coping with cancer, recaps of the latest research advances, and thoughtful discussions on cancer care. And check out other ASCO Podcasts to hear the latest interviews and insights from thought leaders, innovators, experts, and pioneers in oncology. Cancer.Net is supported by Conquer Cancer, the ASCO Foundation, which funds lifesaving research for every type of cancer, helping people with cancer everywhere. To help fund Cancer.Net and programs like it, donate at CONQUER.ORG/Donate.

In this episode of The Good Clean Nutrition Podcast, host Mary Purdy, MS, RDN, speaks with Dr. Taniqua Miller, MD, FACOG, NCMP, a board-certified OB/GYN and national certified menopause practitioner, to discuss how women can improve their health and quality of life during menopause. Tune in as they take a deeper dive into menopause, and how to empower and support women and those assigned female at birth who are preparing for, or navigating, the mid-life health journey. In this episode we'll cover: (5:55) Perimenopause vs. Menopause (11:11) Symptoms of Menopause in Women of Color (13:35) Diet & Lifestyle Factors that Put Women at Higher Risk for Symptoms of Menopause (18:34) Strategies to Support Women in Mid-life (30:28) Hormone Replacement Therapy (35:18) Sexual Wellbeing Through Menopause Dr. Taniqua Miller is a board-certified OB/GYN and national certified menopause practitioner. Dr. Miller trained in psychology at Yale University and then earned her medical degree from Harvard Medical school. Dr. Miller has spent her career empowering women over 40 to live a Boundless Midlife. She is based in Atlanta, GA, and has been recognized for her exceptional care by Atlanta magazine's Top Docs recognition and Emory School of Medicine Educator's Award. For show notes, transcripts, and to learn more about host Mary Purdy, MS, RDN, visit: http://healthcare.orgain.com/podcast/episodes/listen/season/3/episode/28. Be sure to subscribe to this podcast so you never miss a new episode! Disclaimer: This podcast is for informational purposes only and is not intended to be medical advice. The material discussed on this podcast, and displayed on the associated webpage, is not intended to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition or treatment and before undertaking a new health regimen.

James Dahlman is a biomedical engineer who works at the intersection of nanotechnology, molecular biology, and genomics. He is an associate professor at Georgia Institute of Technology and Emory School of Medicine, and the director of the Lab for Precision Therapies. His lab designs drug delivery vehicles that target RNA and other nucleic acids to cells in the body, and uses DNA barcodes to screen thousands of nanoparticles in vivo. He has applied his technology to treat diseases such as heart disease, cancer, inflammation, and pulmonary hypertension. He has also developed new tools for gene editing using CRISPR-Cas9. James has received numerous awards for his research, including the McCamish Foundation Early Career Professorship. His work has been translated via Guide Therapeutics, which was spun out of Georgia Tech and acquired by Beam Therapeutics. He is also a passionate educator and mentor who loves to share his enthusiasm for science with students and the public.

Oral arguments at the Supreme Court are a window into the personalities, beliefs, and behavior of justices. They allow advocates to engage directly with the highest court in the land about how the law should work in practice. And over the last two decades, as country has become increasingly partisan, they've started to sound very different. We talk about how, why, and what's up with all the interrupting. Helping us break it down is Tonja Jacobi, professor of law and the Sam Nunn Chair of Ethics and Professionalism at Emory School of Law. We talk about several of Jacobi's studies on oral arguments, check them out: Justice, Interrupted: The Effect of Gender, Ideology and Seniority at Supreme Court Oral ArgumentsThe New Oral Argument: Justices as AdvocatesSupreme Court Interruptions and Interventions: The Changing Role of the Chief Justice 

Ms. Carrie Huebner, CFCP, PA-C joins discusses alternative and integrative therapy for difficult to treat conditions such as autoimmune disease, chronic pain, and infertility. Carrie Huebner, CFCP, PA-C is a PA, wife, and mother of five miracle babies. Carrie attended the University of Florida obtaining her Bachelor of Health Science and Master of Physical Therapy degree. After several years of struggling with infertility, Carrie and her husband found the help they needed through the Creighton Model and NaProTECHNOLOGY. Inspired by her own infertility journey and improved health and wellness with a more natural approach to medicine, she went on to attend PA school at Emory School of Medicine, graduating with highest honors. While at Emory she was awarded the Georgia Physician Assistant Association Scholarship and was inducted into the Pi Alpha Honor Society. Additionally, she obtained her Masters in Integrative Medicine at George Washington University. Carrie is also a certified FertilityCare Practitioner for the Creighton Model System and a NaProTECHNOLOGY medical consultant. Drawn to evangelization and education, Carrie and her husband provide presentations as well as a personal witness to groups of all ages on marriage and family, fertility awareness/NFP, and infertility. She currently works as an orthopedic surgical PA in Georgia and is excited to be offering family, integrative, and restorative reproductive medicine through Santa Casa Center. [Santa Casa Center – Visit the Website] • [Santa Casa Center – Schedule an Appointment]  

This episode features Dr. Dhaval Desai, Director of Hospital Medicine and Senior Physician at Emory Saint Joseph's Hospital & Assistant Professor of Medicine, Emory School of Medicine & Dr. Shobhna Singh, Assistant Professor of Medicine at the Division of Hospital Medicine at Emory St. Joseph's Hospital. Here, they discuss their background, opportunities and headwinds they're keeping their eyes on, how they're thinking about growth and adding value to their organization, a risk or investment worth making this year, and where they see the best opportunities for growth in the future.Want to network with peers and hear more conversations like this? Apply to be one of our complimentary guest reviewers at our upcoming HIT + Digital Health + RCM Meeting Oct, 3-6 2023 here.

This episode features Dr. Dhaval Desai, Director of Hospital Medicine and Senior Physician at Emory Saint Joseph's Hospital & Assistant Professor of Medicine, Emory School of Medicine & Dr. Shobhna Singh, Assistant Professor of Medicine at the Division of Hospital Medicine at Emory St. Joseph's Hospital. Here, they discuss their background, opportunities and headwinds they're keeping their eyes on, how they're thinking about growth and adding value to their organization, a risk or investment worth making this year, and where they see the best opportunities for growth in the future.Want to network with peers and hear more conversations like this? Apply to be one of our complimentary guest reviewers at our upcoming HIT + Digital Health + RCM Meeting Oct, 3-6 2023 here.

Dr. Arefa Cassoobhoy/Clarkston Community Health Center Dr. Arefa Cassoobhoy is the Medical Director at Clarkston Community Health Center, a non-profit clinic for individuals without adequate health insurance, many of whom are recent immigrants. She is an advocate for health equity and health literacy and serves on the Emory School of Medicine Alumni Board, is the […] The post Dr. Arefa Cassoobhoy, Medical Director at Clarkston Community Health Center appeared first on Business RadioX ®.

Dr. Arefa Cassoobhoy/Clarkston Community Health Center Dr. Arefa Cassoobhoy is the Medical Director at Clarkston Community Health Center, a non-profit clinic for individuals without adequate health insurance, many of whom are recent immigrants. She is an advocate for health equity and health literacy and serves on the Emory School of Medicine Alumni Board, is the […]

Burnout is a state of emotional, physical, and mental exhaustion caused by prolonged stress. A change in venue means moving to a different location, while a change in mindset refers to shifting one's perspective or way of thinking.Knowing what your best life looks like involves identifying your values, goals, and priorities, and aligning your actions and decisions accordingly.Encouraging people to choose their own path in life and exercise their freedom is a positive message of empowerment and self-determination.In this episode with Dr. Taniqua Miller, we are so honored that she has graciously shared her expertise and experience with us.Guest Bio:Women's Health Advocate.Transformational Coach. Unapologetic Hype Girl. Dr. Taniqua Miller is a board-certified OB/GYN and national certified menopause practitioner. She prides herself on her commitment to supporting women and girls through their reproduction transitions and beyond. Through her educational platform, TaniquaMD, she empowers women of color to embrace a boundless midlife. After 14 years in academic medicine, Dr. Miller experienced professional burnout and made the decision to pause her clinical practice. During her time away, she read a devotional giving her a new call to action: Be Boundless. As a first generation American, college graduate, and physician, she now tells her story of burnout and her secret weapon to living a boundless life: quitting! Dr. Miller received her BA in Psychology from Yale University and completed her medical degree from Harvard Medical School. But don't let the Ivy League stats fool you. Dr. Miller's relatability and authenticity brings her audiences and clients closer to the truest versions of themselves. She is a champion of equity in women's healthcare and a committed educator for medical students and trainees of color. She has been recognized for her innovation in education and faculty development by the Society of Academic Specialists in General Obstetrics and Gynecology and the Emory School of Medicine. She is a transformative speaker and professional coach for her signature program, Burnout to Boundless™ group coaching program. Her mission is simple: helping burnt out 1st generation professional women of color quit so that they can live a life of their dreams. https://www.instagram.com/taniquamillermd/https://www.linkedin.com/in/taniquamillermd/

An ethics panel will investigate whether Gwinnett County Commissioner Kirkland Carden violated the county's ethics policy by serving as a strategist for a candidate's failed bid for a legislative seat last year. The complaint was filed by Laurie McClain, who lost to Carden in the 2020 general election race for Commission District 1. She alleges that Carden's role as a campaign consultant for Om Duggal's campaign violated the county's ethics policy, which prohibits officials from taking on employment or rendering services that limit their ability to be impartial in their official duties. This is only the third time since the policy's inception that a commissioner will face an ethics panel. Georgia Gwinnett College is seeking permission from the University System of Georgia to expand its athletic department and add men's and women's basketball programs. GGC's President, Jann L. Joseph, confirmed the news after the groundbreaking for a new convocation center that will include a basketball arena. The first step in launching the teams is to file paperwork with the university system, and if approved, the teams would compete in the NAIA like GGC's other athletic programs. GGC's athletic department currently offers six athletic programs, including men's and women's soccer, men's and women's tennis, baseball, and softball programs. Fourth-year medical students at Philadelphia College of Osteopathic Medicine in Suwanee and Moultrie have achieved a 100% completion rate into postgraduate positions, according to Tina Woodruff, senior advisor to the provost. Residency placement lists indicate that since 2016, 34% of PCOM Georgia's students remain in Georgia to complete their residencies. Andrea Mann, dean and chief academic officer of PCOM Georgia's osteopathic medicine program, said that almost three quarters of the fourth-year students will pursue careers in Georgia's targeted core specialty areas. Students were matched with programs at prestigious institutions such as Emory School of Medicine and Morehouse School of Medicine. The Gwinnett County Public Library's New Start Entrepreneurship Incubator program has awarded $5,000 grants to three graduates for their business pitches. The program provides business education for formerly incarcerated individuals, including in-person classes, online coursework, and mentorship. Bridgette Simpson, co-founder of Barred Business, won $2,500 for the Outstanding Business Pitch, Dewy Ventura Joa, owner of CholoMMA, received $1,500 for second place, and Mia Jacobs, founder of DeCCRO, won $1,000 for third place. The program aims to support the re-entry population, which in Georgia is disproportionately made up of people of color and minority populations. GDP's Will Hammock joins us for our Gwinnett Sports update presented by Tom Wages Funeral Home. Putt Nation, a high-end miniature golf course and restaurant combo, has opened in Buford, promising to "take miniature golf to the next level." With two nine-hole courses featuring custom lighting, sound effects, obstacles, and video challenges, the course aims to offer an immersive experience for all ages. The facility also has a self-serve tap wall offering a wide selection of beer, wine, and cocktails for visitors to try without committing to a full serving. Putt Nation is open from 11 a.m. until 11 p.m. Monday through Thursday and 11 a.m. until 1 a.m. on weekends, accommodating group events and parties for team building and birthday celebrations. The Georgia Gwinnett College Foundation has received an Innovative Education Fund Prototype Grant from the Georgia Foundation for Public Education to support math tutoring for elementary school students in need of targeted support. The $20,000 grant will fund an innovative education program piloted at Alford Elementary School in Gwinnett County, where professional development for tutors and collaboration with teachers and administrators have been deemed essential components of the program. Dr. Amber Ebert, assistant professor in science education and department chair of Secondary Education for Georgia Gwinnett College, collaborated with GGC's Advancement team to write the proposal for the grant. For more information be sure to visit www.bgpodcastnetwork.com   https://www.lawrencevillega.org/  https://www.foxtheatre.org/  https://guideinc.org/  https://www.psponline.com/  https://www.kiamallofga.com/  https://www.milb.com/gwinnett  https://www.fernbankmuseum.org/  www.atlantagladiators.com              See omnystudio.com/listener for privacy information.

Burnout has become a common occurrence among American workers, affecting over half of the population.  In this episode, Dr. Taniqua Miller, a physician and life coach, shares her personal experience with burnout and offers insights into how individuals can overcome it. Burnout symptoms include mental and physical exhaustion, cynicism, feeling ineffective, isolation, overwhelm, anxiety, and numbing behaviors like overeating or excessive drinking. Dr. Miller talks about the importance of self-evaluation, building self-trust and compassion, and identifying personal strengths to cultivate resilience.  Her program, Burnout to Boundless, is designed to help first-generation women of color navigate their burnout journey and transform their mindset to live a more boundless life.  If you're looking to overcome burnout and reclaim your life, this episode will provide a valuable resource for you. Highlights Burnout as a common occurrence among American workers The negative health consequences of chronic stress, including weight gain Dr. Taniqua Miller's personal experience with burnout as a physician Symptoms of burnout Strategies for improving burnout How to cultivate self-trust  Counting wins and changing the negative narrative about oneself Dr. Taniqua Miller's program, Burnout to Boundless Changing the mindset to live a boundless life Connect with Dr. Taniqua: Website | taniquamd.com Instagram |  @taniquamillermd LinkedIn | Taniqua Miller MD NCMP About Dr. Taniqua: Dr. Taniqua Miller is a board-certified obstetrician/gynecologist with a special focus in midlife/menopause health. She received her undergraduate degree in psychology at Yale University. After completing her medical degree at Harvard Medical School, she went on to complete her residency training in obstetrics and gynecology at the University of Virginia in Charlottesville, VA. As a 1st generation college graduate and physician, she is a committed educator and advocate for underrepresented medical students and physician trainees. She has been recognized by the Emory School of Medicine and the Association of Professors in Gynecology and Obstetrics for her teaching excellence and innovative curriculum development. After 14 years of practice, Dr. Miller took a step back from clinical care to center herself and her journey of burnout. She tells her own story of professional burnout to empower other women over 40 to live a boundless midlife. She is wife, mother of three children, and the founder of TaniquaMD, an educational platform for women in midlife. In her spare time, she loves sleep, visits to the beach, and hanging out on the couch with her family.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

Frank Schaeffer In Conversation with Author Rev. G. Scott Morris, Chief Executive Officer of Church Health in Memphis, Tennessee, exploring his book, Care: How People of Faith Can Respond to Our Broken Health System._____LINKSwww.churchhealth.orgBOOKCare: How People of Faith Can Respond to Our Broken Health System_____Rev. G. Scott Morris, MD, a leading voice in the field of faith and health, is the founder and chief executive officer of Church Health in Memphis, Tennessee, which opened in 1987 to provide quality, affordable health care for working, uninsured people and their families and has grown into the largest charitably funded faith-based health care ministry of its type. Thanks to a broad base of financial support from the faith community, and the volunteer help of doctors, nurses, dentists and others, Church Health provides tens of thousands of patient visits each year. An active family practice physician, Dr. Morris also is ordained in the United Methodist Church. He holds an MDiv from Yale Divinity School and an MD from Emory School of Medicine. An ex-evangelical boomer, a middle-aged gay artist, and a frazzled stay-at-home mom walk into a bar, share a table, and go deep about some of life's big questions.Join Frank, Ernie, and Erin as they share stories of love, sex, grief, religion and so much more. This is “Love in Common.”Visit LoveInCommon.org to Subscribe on your favorite Podcast platform. Support the show_____In Conversation… with Frank Schaeffer is a production of the George Bailey Morality in Public Life Fellowship. It is hosted by Frank Schaeffer, author of Fall In Love, Have Children, Stay Put, Save the Planet, Be Happy. Learn more at https://www.lovechildrenplanet.comFollow Frank on Substack, Facebook, Twitter, and YouTube. https://frankschaeffer.substack.comhttps://www.facebook.com/frank.schaeffer.16https://twitter.com/Frank_Schaefferhttps://www.youtube.com/c/FrankSchaefferYouTube In Conversation… with Frank Schaeffer PodcastApple Podcasts: https://podcasts.apple.com/us/podcast/in-conversation-with-frank-schaeffer/id1570357787NEW: Love In Common Podcast with Frank Schaeffer, Ernie Gregg, and Erin BagwellApple Podcasts: https://podcasts.apple.com/us/podcast/love-in-common/id1665307674

Goldie Taylor is a veteran journalist, cable news political analyst and human rights activist. Currently a contributing editor at The Daily Beast, where she writes about national politics and social justice issues, Taylor has been a working journalist for over thirty-five years. She got her start as a staff writer at the Atlanta Journal Constitution and as a desk assistant with CBS News Atlanta. The former television news and communications executive has been featured on nearly every major network—including NBC News, MSNBC, ABC News, BBC, BET News, SkyNews, CNN and HLN—and she has been a guest on programs such as HBO's Real Time with Bill Maher, The Dr. Phil Show, The Steve Harvey Show, Tom Joyner Morning Show, and Good Morning America. Taylor is a frequent guest on a full host of local and national radio shows, including NPR's All Things Considered, 1A and Barbershop, and has been regularly published in print and digital publications. In recent years, she has written for Rolling Stone, Salon, Atlanta Journal Constitution, Creative Loafing, St. Louis Post Dispatch, The Grio, Playboy, Rolling Stone, Huffington Post, CNN.com, MSNBC.com, Ebony, and Essence among others. In November 2015, Taylor penned the cover story for Ebony Magazine about the legacy of comedic icon Bill Cosby and made a cameo appearance on BET's Being Mary Jane. She was a contributing producer for “CNN Presents: The Atlanta Child Murders” and has been an executive consultant to the presidents of both NBC News and CNN Worldwide. A sought-after public speaker, Taylor has addressed audiences at—among others—the National Center for Civil and Human Rights, Harvard University, Morehouse College, Emory School of Law, Princeton University, Duke School of Law, National Association of Black Journalists, University of Missouri School of Journalism and The King Center. A somewhat less than devoted runner, late blooming golf, and self-professed connoisseur of mediocre whiskey, Taylor has three grown children and three grandchildren. She lives in Boston where she is senior vice president and chief communications and marketing officer at Dana-Farber Cancer Institute. MORE: goldietaylor.com

Ajay K. Nooka, MD, Associate Professor of Hematology and Medical Oncology at Emory School of Medicine, discusses the updated efficacy and safety results from the phase 1/2 MajesTEC-1 study evaluating teclistamab in patients with relapsed or refractory multiple myeloma.Multiple myeloma is a rare blood cancer associated with uncontrolled growth of plasma cells. Abnormal plasma cells – also known as myeloma cells – interfere with the production of healthy blood cells in the bone marrow. Symptoms of multiple myeloma may include: bone pain (particularly in the chest and spine), frequent infections, weakness or numbness in the legs, fatigue, confusion, excessive thirst, and constipation. While the disease is treatable, relapses are common and some patients are refractory to first line, and subsequent, therapies.

Friday on Political Rewind: On Jan. 21, 2020, the first case of COVID-19 was detected in the U.S.. Since then, more than 2 million Georgians contracted the virus and nearly 40,000 have died. As a milder variant goes around this winter, we ask a panel of health experts how to best protect ourselves. The panel Professor Amber Schmidtke, @AmberSchmidtke, medical educator and public health microbiologist Dr. Carlos del Rio, @CarlosdelRio7, executive associate dean, Emory School of Medicine and Grady Health System Professor Rodney Lyn, Dean of School of Public Health, Georgia State University Timestamps: 0:00 - Introductions 5:00 - Updated COVID numbers 12:00 - Home testing and testing numbers 14:00 - COVID fatigue 16:00 - Importance of boosters 19:00 - Regional hotspots in Georgia 21:00 - Reliability of home tests 26:00 - Disparities between communities of color 32:00 - Impact of health care in Georgia? 38:00 - Rural vs. urban divide 42:00 - Maternal mortality rates 45:00 - Attacks on health care workers during the pandemic, misinformation 52:00 - HIV cases update Monday on Political Rewind: The AJC's Patricia Murphy joins the panel.

Deborah Simkin, M.D., is a board-certified child, adolescent and adult psychiatrist specializing in Complementary and Integrative (CIM) or Functional Psychiatry for children, adolescents and adults. She is also board certified by the American Board of Integrative and Holistic Medicine and in Neurofeedback and specializes in LORETA neurofeedback. Dr. Simkin uses non-medical and medical interventions that include natural products, meditation, cognitive behavior therapy, genetic testing, validated screening instruments and nutrition, after a thorough bio/psycho/social evaluation is done. Dr. Simkin trained at Harvard's McLean and Mass General Hospitals in child and adolescent psychiatry. She is presently Co-Chair of the American Academy of Child and Adolescent Psychiatry's (AACAP) Committee on Integrative Medicine. In that position, she works with the National Institute of Complementary and Integrative Medicine (NCCIM) at the National Institute of Health (NIH) to increase research among child and adolescent psychiatrists.  She has written numerous articles and chapters and lectures throughout the country. She is a Clinical Assistant Professor at Emory School of Medicine where she teaches CIM.

QUOTES FOR REFLECTION“Life has no meaning the moment you lose the illusion of being eternal.”~Jean-Paul Sartre (1905-1980), French existentialist philosopher “To be always relevant, you have to say things which are eternal.”~Simone Weil (1909-1943), French philosopher, mystic and political activist “[T]here is, finally, no intelligible (much less persuasive) secular version of the conviction that every human being is sacred; the only intelligible versions are religious.”~Michael J. Perry, legal scholar at Emory School of Law, in The Idea of Human Rights (Oxford Press, 2000) “The creation of the world was a very great thing, but not so great as the incarnation of Christ. It was a great thing for God to make the creature, but not so great as for the Creator himself to become a creature. Many great things were accomplished between the fall of man and the incarnation of Christ: but God becoming man was greater than all.”~Jonathan Edwards (1703-1758) in A History of the Work of Redemption “Authority without wisdom is like a heavy axe without an edge, fitter to bruise than polish.”~Anne Bradstreet (1612-1672), American Puritan poet “The fool doth think he is wise, but the wise man knows himself to be a fool.”~William Shakespeare (1564-1616), in As You Like It “Yeah. After the first 20 years of toiling, sure. Then it was overnight.”~James Brown, host of The NFL Today on CBS, after being told he was an “overnight success” “Behold, he who keeps Israelwill neither slumber nor sleep.The Lord is your keeper the Lord is your shade on your right hand.”~Psalm 121:4-5 (ESV)SERMON PASSAGEIsaiah 9:1-7 (ESV) Isaiah 9 1 But there will be no gloom for her who was in anguish. In the former time he brought into contempt the land of Zebulun and the land of Naphtali, but in the latter time he has made glorious the way of the sea, the land beyond the Jordan, Galilee of the nations.2 The people who walked in darkness  have seen a great light;  those who dwelt in a land of deep darkness,  on them has light shone.3 You have multiplied the nation;  you have increased its joy;  they rejoice before you  as with joy at the harvest,  as they are glad when they divide the spoil.4 For the yoke of his burden,  and the staff for his shoulder,  the rod of his oppressor,  you have broken as on the day of Midian.5 For every boot of the tramping warrior   in battle tumult  and every garment rolled in blood  will be burned as fuel for the fire.6 For to us a child is born,  to us a son is given;  and the government shall be upon his shoulder,  and his name shall be called  Wonderful Counselor, Mighty God,  Everlasting Father, Prince of Peace.7 Of the increase of his government and of peace  there will be no end,  on the throne of David and over his kingdom,   to establish it and to uphold it  with justice and with righteousness  from this time forth and forevermore.  The zeal of the Lord of hosts will do this. Isaiah 4027 Why do you say, O Jacob,  and speak, O Israel, “My way is hidden from the Lord,   and my right is disregarded by my God”?28 Have you not known? Have you not heard?  The Lord is the everlasting God,  the Creator of the ends of the earth.  He does not faint or grow weary;  his understanding is unsearchable.29 He gives power to the faint,  and to him who has no might he increases strength.30 Even youths shall faint and be weary,  and young men shall fall exhausted;31 but they who wait for the Lord  shall renew their strength;  they shall mount up with wings like eagles;  they shall run and not be weary;  they shall walk and not faint. Isaiah 4110 fear not, for I am with you;  be not dismayed, for I am your God;  I will strengthen you, I will help you,  I will uphold you with my righteous right hand. Isaiah 5310 Yet it was the will of the Lord to crush him;  he has put him to grief;  when his soul makes an offering for guilt,  he shall see his offspring; he shall prolong his days;  the will of the Lord shall prosper in his hand.11 Out of the anguish of his soul  he shall see and be satisfied;  by his knowledge shall the righteous one,  my servant, make many to be accounted righteous,  and he shall bear their iniquities. Isaiah 6316 For you are our Father,  though Abraham does not know us,  and Israel does not acknowledge us;  you, O Lord, are our Father,  our Redeemer from of old is your name.

Learn more about Dr. Taniqua Miller's Boundless Midlife™ Burnout Recovery ProgramFollow her on InstagramAbout Taniqua Miller, MDDr. Taniqua Miller received her undergraduate degree in psychology at Yale University. After completing her medical degree at Harvard Medical School, she completed her residency training in obstetrics and gynecology at the University of Virginia in Charlottesville, VA. As a 1st generation college graduate and physician, she is a committed educator and advocate for underrepresented medical students and physician trainees. She has been recognized by the Emory School of Medicine and the Association of Professors in Gynecology and Obstetrics for her teaching excellence and innovative curriculum development. After 14 years of practice, Dr. Miller took a step back from clinical care to center herself and her journey of burnout. She tells her own story of professional burnout to empower other women over 40 to live a boundless midlife. She is a wife, mother of three children, and the founder of TaniquaMD, an educational platform for women in midlife. In her spare time, she loves to sleep, visit the beach, and hang out on the couch with her family.

How do you talk to your children about drugs? There is increase normalization and commercialization of drugs, especially marijuana, preying on kids. If parents don't talk to kids about drugs, they will learn about it from Snap Chat or Drug Dealers. Addiction is a disease on the young brain with serious health harms.  Dr. Shannon Murphy is a pediatrician and expert in messaging to children and young adults. Dr. Shannon Murphy is a pediatrician who currently volunteers her time in drug education. Dr. Murphy received her undergraduate degree at Vanderbilt University and her M.D. from Emory School of Medicine. She completed her pediatric training at the Children's Hospital of Philadelphia and subsequently worked as a primary care pediatrician in a community group practice in Alabama. She has served on a Practice Advisory Committee on Adolescent Substance Use for the American Academy of Pediatrics and currently sits on the Board of Directors for National Families in Action (NFIA), a national non-profit substance use prevention organization. Additionally, Dr. Murphy serves on the Expert Physician Council for the International Academy on the Science and Impact of Cannabis (IASIC), an international non-profit organization of doctors educating on marijuana. Dr. Murphy's primary focus is on adolescent health and well-being. She is actively involved in developing education-based community outreach programs throughout the state with a concentration on marijuana education for teens, parents, and community organizations. NIDA - is a resource Dr. Murphy referred to.

When it comes to treating cancer, what was not possible just a few years ago is now possible. In this episode, Dr. Suresh S. Ramalingam, the executive director of Winship Cancer Institute of Emory University, speaks with Emory School of Medicine student Carey Jansen about the advances in research, patient care, and education that are leading to long-term survival and a better quality of life for people with cancer. Our GDPR privacy policy was updated on August 8, 2022. Visit acast.com/privacy for more information.

#086 [CEU Podcast] - Chronic pain impacts more than 1 in 5 adults living in the United States and can have a significant negative impact on all aspects of a person's life, including ability to work or attend school, finances, social and romantic relationships, and sense of self. Research shows that chronic pain is associated with an increase in risk for depression and suicide. Yet, high rates of stigma, bias in health care, and limited access to trained mental health providers  contributes to people living with chronic pain not receiving the care they need. This CEU podcast will address the widespread impact of chronic pain on the whole person, with focus on the pain-depression cycle.After listening to this episode, you'll be able to: Identify 3 psychosocial ways in which quality of life is impacted by chronic painDiscuss why it is important to attend to both mental/emotional wellness and physical health when working with people chronic painExplain the bidirectional relationship between chronic pain and depressionToday's guest, Dr. Jennifer Steiner, is a board certified clinical health psychologist, founder of Beyond the Body Health Psychology Services, LLC, Co-Director of Center for Mental Health & Aging's Continuing Education Program, Adjunct Faculty at Emory School of Medicine, Board Member of the Georgia Psychology Association Board of Directors, Co-Chair of the Continuing Education Committee for Georgia Psychological Association, and Member of the Committee on Health Psychology and Integrated Practice.  Click here to learn more about earning CEUs for listening to this podcast.CEUs available for Social Workers, Psychologists, Therapists, Aging Life Care Experts.

After losing a leg as a toddler and struggling with repeated infections, Cassandra Quave became obsessed, even as a young child, with preventing infection. That obsession has led her from Florida's swamps to the Peruvian Amazon in pursuit of plants that can defeat antibiotic-resistant superbugs. Her stories are personal, riveting and inspiring, and they offer hope for a medical future that's quite different from our present. Guest: Cassandra Quave, author of "The Plant Hunter: A Scientist's Quest for Nature's Next Medicines" and Associate Professor of Dermatology and Human Health at Emory School of Medicine

Perhaps no jurisdiction has conducted more Zoom jury trials since the start of the pandemic than King County (Seattle), Washington.  In this episode, Ben and Rahul speak with King County Superior Court Judge, Matthew Williams, about lessons he has learned managing Zoom trials, including his experience conducting jury selection. trial, witness examination, cross examination, use of exhibits, and his observations concerning the key differences between Zoom and in-person trials. About Judge WilliamsMatthew W. Williams is a Superior Court Judge for the State of Washington. Almost all of his time off the bench is devoted to Rule of Law and AntiCorruption Initiatives in pre/post conflict nations and emerging democracies around the world. He has such led initiatives in Central Asia, South America, Africa, the Middle East, and within the former Soviet Republics. He also has been invited to provide training and consultations for justice systems within those regions in culturally specific advocacy, case-management, transparency/ “open courts”, and judicial process and demeanor. Since 1985 he has served as an operational consultant and trainer in complex information gathering and analysis environments. Judge Williams teaches at the Washington State Judicial College and serves as member of Washington State Superior Court Judges Association (SCJA) Ethics and Education Committees. He serves as a trainer and presenter for the SCJA and the Washington State District and Municipal Judges Association (DMCJA) as well as the National Judicial College (NJC), and the National Center for State Courts (NCSC). Judge Williams serves on the Advisory Board of the Institute for the Global Understanding of the Rule of Law (IGUL), and as an Advisor to the Civil Jury Project at NYU School of Law. He is a member of the National Center for State Courts (NCSC) Post-Pandemic Planning Workgroup, and has provided consultation and training to judges throughout the United States on every aspect of remote/virtual operations. He was selected as 2021 Trial Judge of The Year by the Washington Chapter of the American Board of Trial Advocates (ABOTA). Judge Williams has taught Trial Advocacy at Seattle University School of Law (University of Puget Sound) since 1991. In 2020 he developed and conducted the first fully virtual Trial Advocacy program at Seattle University, which included both traditional in-person advocacy skills as well as the emerging skill sets associated with remote advocacy. Judge Williams has served many terms as faculty team leader for the renowned Kessler-Eidson Trial Techniques Program at Emory School of Law in Atlanta, Georgia. Additionally, from 2000-2016 he served as a Director of the National Institute of Trial Advocacy (NITA) Trial, Deposition, and Public Service Programs. In 2016 NITA awarded Judge Williams the Prentice Marshall Award for the Development of Innovative Teaching Methods. Judge Williams began his legal career(s) with the Attorneys General of Nebraska, Iowa, and Washington State. He handled death penalty and criminal appeals matters as well as complex commercial and tax litigation. He left State service and supervised Federal drug, weapons, and aviation enforcement. He then served as the Supervising Attorney for the City of Seattle's Major Civil Litigation unit. He left public service in 1994 and became the Managing Attorney of a mid-sized law office until 2003. From 2003 to 2010, Judge Williams served as a general manager for a national insurance carrier where he managed multiple business units across the nation while implementing best practices and data driven decision making. Along the way, he served as a Special Disciplinary (Ethics) Counsel for the Washington State Bar Association, as a member of the Enforcement of Lawyer Conduct (ELT) Task Force, and as a Trustee of the Washington Defense Trial Lawyers (WDTL). In 2010 he was elected to the King County District Court. He was elected to the King County Superior Court in 2016. Judge Williams earned a Bachelor of Science in Economics from the University of Nebraska (1980), and a Juris Doctorate from the University of Nebraska School of Law (1983). He has logged thousands of hours as pilot-in-command. He holds the rank of Black Belt in Tae Kwon Do and has served as a martial arts and personal defense instructor.   

Author Dr. J. David Prologo talks about his new book “The Catching Point Transformation” and a brand new approach to weight loss and focuses on overcoming the body's resistance to change! Dr. Prologo is dual-board certified in obesity medicine and interventional radiologist from Emory School of Medicine and spent over 20 years analyzing diet attrition and why do diets always fail and why we do we blame patients for the failure?! His book is also created to ease the transition and quiet the body's resistance so everyone can have fun, feel confident and be successful when engaging in healthy living! Find out more the amazing by Dr. J. David Prologo on Amazon and www.drprologo.comtoday! #drjdavidprologo #drdavidprologo #davidprologo #author #obesity #radiologist #thecatchingpointtransformation #emoryschoolofmedicine #diet #weightloss #weightprogram #amazon #audible #iheartradio #spreaker #spotify #itunes #googleplay #applemusic #youtube #podbean #anchorfm #mikewagner #themikewagnershow #mikewagnerdrjdavidprologo #themikewagnershowdrjdavidprologo --- Send in a voice message: https://anchor.fm/themikewagnershow/message Support this podcast: https://anchor.fm/themikewagnershow/support

Tuesday on Political Rewind: The new year brings the same COVID frustrations for people across Georgia and the country. Dr. Carlos del Rio returned to the show to share insights and advice on coping with the latest wave of the coronavirus. Journalists Ellen Eldridge and Tamar Hallerman also weigh in on the impact of the virus as we enter the start of another year with the pandemic. The Panel: Dr. Carlos del Rio — Executive associate dean, Emory School of Medicine & Grady Health System Ellen Eldridge — Senior health care reporter, Georgia Public Broadcasting Tamar Hallerman — Senior reporter, The Atlanta Journal-Constitution

This is She's On Call, a weekly show hosted by NYC-based doctors ENT specialist Dr. Sujana Chandrasekhar and general surgeon Dr. Marina Kurian.We're talking about cardiac health and millennial wellness with Dr. Modele Ogunniyi, cardiologist and professor at Emory School of Medicine, and Dr. Jay-Sheree Allen, family medicine physician and host of Millennial Health Podcast. Ask them anything! The physicians and their guests' views are their own and do not represent any institution. Please contact your doctor for any personal questions.Please hit share and join us live on Facebook, Twitter, Instagram, and YouTube at @shesoncall.Hashtag: #ShesOnCall​​​​

Dr. Beckford interviews Dr. Alfy on this episode of the podcast. You don't want to miss this episode:

Wednesday on Political Rewind: Two top public health experts, epidemiologist and Emory School of Medicine Associate Dean Dr. Carlos del Rio and Dr. Amber Schmidtke, the writer behind The COVID Digest, an informative newsletter covering COVID-19 trends in Georgia, joined our panel to answer questions about the current COVID-19 surge. Does the latest data tell us we've reached the peak in new cases of COVID-19 in the state? Are hospitals still facing a care crisis? How safe are people who are fully vaccinated? How long will their protection likely last and when might they need booster shots? If you are vaccinated, why should you wear a mask at the grocery store or a movie theater? The panel also discussed challenges faced by people behind the state's public health efforts. During a recent meeting of the state's public health board, Public Health Commissioner Dr. Kathleen Toomey praised the resolve of health care and public health workers in the face of abuse and ridicule. Del Rio said he is noticing low morale among health care workers over a year into the pandemic. "At the beginning of this pandemic, people were applauding and they were cheering for health care workers and bringing food to hospitals," he said. "Right now, there's a protest outside hospitals. There's anger against health care workers. And many people are leaving the health care field as a result of that. And I think we need to really realize that this could have tremendous consequences, not just for COVID, but for many other diseases." Panelists: Dr. Amber Schmidtke — Chair of the Division of Natural Sciences and Mathematics at the University of Saint Mary, and writer, The COVID Digest Dr. Carlos del Rio — Associate dean, Emory School of Medicine and Professor of Medicine, Infectious Disease Division, at Emory University Greg Bluestein - Political reporter, The Atlanta Journal-Constitution

6.21.21 #RolandMartinUnfiltered: SCOTUS rules against NCAA; Roland slaps down Bill Maher; Essence Festival Throwback by Coca-Cola; GOP Senator who opposed Juneteenth holiday gets booed out of a Juneteenth celebration; Emory School of Medicine apologized to a Black doctor more than 60 years after denying his application; GOP Manchin voting compromise backlash; Out of spite over Texas Dems halting voter suppression legislation, Gov. Abbott vetoed the state budget that funds the legislature; San Bernardino deputy kicks man in the head during an arrest; Fitness Expert Gym Jonez breaks down if sweating means you're burning fat. Support #RolandMartinUnfiltered via the Cash App ☛ https://cash.app/$rmunfiltered or via PayPal ☛ https://www.paypal.me/rmartinunfiltered #RolandMartinUnfiltered is a news reporting platform covered under Copyright Disclaimer Under Section 107 of the Copyright Act 1976, allowance is made for "fair use" for purposes such as criticism, comment, news reporting, teaching, scholarship, and research. Learn more about your ad-choices at https://www.iheartpodcastnetwork.com See omnystudio.com/listener for privacy information.